Revive Therapeutics Enters License Agreement for Cannabinoids-Based Therapeutics

Revive Therapeutics (TSXV:RVV; OTCQB:RVVTF) announced it entered into a license agreement with South Carolina Research Foundation.
As quoted in the press release:

Revive will acquire an exclusive license from SCRF to develop and commercialize a portfolio of patents based on cannabinoid-based therapeutics, such as Cannabidiol, in the treatment of liver diseases.
“The licensing of the patent portfolio of cannabinoids in the treatment of liver diseases is an important milestone for Revive, as we continue to realize our objective of commercializing treatments to address unmet medical needs in liver diseases,” said Craig Leon, Chief Executive Officer of Revive. “We will continue focusing on commercializing our candidates of cannabinoid-based therapies and on expanding our product pipeline in the field of liver disease such as autoimmune hepatitis, liver cirrhosis, non-alcoholic steatohepatitis (NASH), and non-alcoholic fatty liver disease (NAFLD).”

Click here to read the full press release.

Source: www.marketwired.com